Assessment of Mannose Modified Nanoliposome of Excretory-Secretory Antigens Against Acute Toxoplasmosis in Mice | ||||
| Zagazig University Medical Journal | ||||
| Volume 31, Issue 8, August 2025, Page 4251-4263 PDF (1.92 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/zumj.2025.385456.3956 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Amira Abd El lateef Saleh1; Dalia Abd El Khalik Abo El Maaty2; Afaf Abdelraaouf Taha3; Amany Abd El Rahman Maghawry4; Shaimaa Elsayed Ashoush   5
| ||||
| 1Assistant professor of Medical Parasitology department , faculty of Medicine , Zagazig University | ||||
| 2Professor of medical parasitology , faculty of medicine, zagazig university | ||||
| 3Medical parasitology department, faculty of medicine, Zagazig university | ||||
| 4Lecturer of Medical Parasitology, Faculty of Medicine, Zagazig UNiversity | ||||
| 5Lecturer of Medical Parasitology, faculty of Medicine, Zagazig University | ||||
| Abstract | ||||
| Background: Toxoplasma gondii is an obligate intracellular protozoan that cause the infectious disease toxoplasmosis. Currently, no effective vaccine exists against this parasite for humans. Therefore, this study aimed to evaluate the efficacy of different vaccine candidates including, excreted/ secreted antigens (ESAs), alum-adjuvanted ESAs, mannose-modified nanoliposomes of ESAs, and mannose-modified nanoliposomes of ESAs with alum against acute T. gondii (RH strain) infection in BALB/c mice. Methods: This study started with the preparation of ESAs, and mannose-modified nanoliposomes of ESAs and mice were then immunized separately. Their anti-Toxoplasma antibody and iNOS levels in serum were then measured using ELISA before challenging infection. Subsequently, mice were challenged with T. gondii tachyzoites. Afterward, we assessed the peritoneal fluid's burden of the parasite, survival time, serological anti-Toxoplasma IgG antibodies and iNOS levels, and histopathology of liver and spleen. Results: The vaccinated groups with either alum adjuvanted ESAs or mannose-modified nanoliposome adjuvanted ESAs showed significant reduction in tachyzoites counts and prolonged survival time in a dose-dependent manner. Additionally, there was a significant increase in both anti-Toxoplasma IgG and iNOS levels (P<0.001). Furthermore, there was a considerable reduction in the hepatic and splenic pathological alterations, along with fewer numbers of the parasite than mice received ESAs alone. Notably, vaccination with mannose-modified nanoliposome ESAs yielded more promising results compared to alum-adjuvanted ESAs. Conclusion: mannose-modified nanoliposome may be regarded as an appropriate adjuvant and antigen vehicle system for vaccination against Toxoplasma. | ||||
| Keywords | ||||
| RH Toxoplasma; Excreted/secreted antigens; Nanoliposomes; iNOS; Anti-Toxoplasma IgG | ||||
|
Statistics Article View: 42,997 PDF Download: 34 |
||||
